Company

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis
Auto-immuneClinical trial approval / initiation

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis

Hinova Pharmaceuticals Inc. (SHA: 688302) announced that its self‑developed investigational drug HP570 received formal Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the treatment…

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Sanofi's Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment
NASDAQ: SNYRare / orphan disease drugs

Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer
ADC / XDCBio-Thera Solutions

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer

AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit
AstraZenecaAZ

AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit

EMA Panel Recommends Brukinsa Tablet Formulation for Approval
BeiGeneBeOne Medicines

EMA Panel Recommends Brukinsa Tablet Formulation for Approval

Show More